Stock HEPA HEPION PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Hepion Pharmaceuticals, Inc.

Equities

HEPA

US4268973025

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-04-19 pm EDT 		5-day change 1st Jan Change
2.01 USD -4.82% Intraday chart for Hepion Pharmaceuticals, Inc. -8.22% -37.96%
Apr. 19 Hepion Pharmaceuticals Starts Wind-Down Activities in Phase 2b ASCEND-NASH Trial MT
Apr. 16 Hepion Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Hepion Pharmaceuticals Starts Wind-Down Activities in Phase 2b ASCEND-NASH Trial
MT
Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH’ Trial
AQ
Hepion Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Hepion Pharmaceuticals Strengthens Board of Directors with Appointment of Michael Purcell
AQ
Hepion Pharmaceuticals, Inc. Appoints Michael Purcell to Its Board of Directors
CI
Hepion Pharmaceuticals, Inc. Announces Board Changes
CI
Hepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross Proceeds
AQ
Hepion Pharmaceuticals, Inc. Announces Resignation of Anand Reddi from the Board of Directors
CI
Hepion Pharmaceuticals to Present at NASH-TAG 2024
AQ
North American Morning Briefing : Futures Pause -2-
DJ
Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value
CI
Hepion Pharmaceuticals Approves Restructuring Plan to Preserve Capital, Launches Strategic Review Process
MT
Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management Changes
AQ
Hepion Pharmaceuticals, Inc. Announces Resignation of Robert Foster as Director
CI
Hepion Pharmaceuticals, Inc. Announces CEO Changes
CI
Hepion Pharmaceuticals to Present at the 7th Obesity & NASH Drug Development Summit
AQ
Hepion Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Hepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-week Phase 2 Study of Advanced (F3) MASH Liver Disease
AQ
Hepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-Week Phase 2 Study of Advanced (F3) Mash Liver Disease
CI
Hepion Pharmaceuticals Schedules Conference Call to Review Additional Efficacy Data from Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial of Rencofilstat
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. HEPA Stock
  4. News Hepion Pharmaceuticals, Inc.